These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15890924)

  • 1. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    Barassi C; Soprana E; Pastori C; Longhi R; Buratti E; Lillo F; Marenzi C; Lazzarin A; Siccardi AG; Lopalco L
    J Virol; 2005 Jun; 79(11):6848-58. PubMed ID: 15890924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.
    Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L
    New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells.
    Bomsel M; Pastori C; Tudor D; Alberti C; Garcia S; Ferrari D; Lazzarin A; Lopalco L
    AIDS; 2007 Jan; 21(1):13-22. PubMed ID: 17148963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge.
    Zuber B; Hinkula J; Vödrös D; Lundholm P; Nilsson C; Mörner A; Levi M; Benthin R; Wahren B
    Virology; 2000 Dec; 278(2):400-11. PubMed ID: 11118363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S; Kennedy M; King LR; Golding H
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.
    Pastori C; Diomede L; Venuti A; Fisher G; Jarvik J; Bomsel M; Sanvito F; Lopalco L
    J Virol; 2014 Apr; 88(7):3623-35. PubMed ID: 24403594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro.
    Lopalco L; Barassi C; Pastori C; Longhi R; Burastero SE; Tambussi G; Mazzotta F; Lazzarin A; Clerici M; Siccardi AG
    J Immunol; 2000 Mar; 164(6):3426-33. PubMed ID: 10706739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.
    Losana G; Bovolenta C; Rigamonti L; Borghi I; Altare F; Jouanguy E; Forni G; Casanova JL; Sherry B; Mengozzi M; Trinchieri G; Poli G; Gerosa F; Novelli F
    J Leukoc Biol; 2002 Oct; 72(4):735-42. PubMed ID: 12377943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.
    Meng G; Wei X; Wu X; Sellers MT; Decker JM; Moldoveanu Z; Orenstein JM; Graham MF; Kappes JC; Mestecky J; Shaw GM; Smith PD
    Nat Med; 2002 Feb; 8(2):150-6. PubMed ID: 11821899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
    Zaunders JJ; Kaufmann GR; Cunningham PH; Smith D; Grey P; Suzuki K; Carr A; Goh LE; Cooper DA
    J Infect Dis; 2001 Mar; 183(5):736-43. PubMed ID: 11181150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes.
    Patterson BK; Czerniewski M; Andersson J; Sullivan Y; Su F; Jiyamapa D; Burki Z; Landay A
    Clin Immunol; 1999 Jun; 91(3):254-62. PubMed ID: 10370370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV.
    Wu K; Xue X; Li M; Qin X; Zhang C; Li W; Hao Q; Wang Z; Liu Q; Zhang W; Zhang Y
    Protein Expr Purif; 2013 Jun; 89(2):124-30. PubMed ID: 23542826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
    J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.